Category
page 1Ketoximes

dimethylglyoxime
Dimethylglyoxime is a chemical compound described by the formula CH3C(NOH)C(NOH)CH3. Its abbreviation is dmgH2 for neutral form, and dmgH− for anionic form, where H stands for hydrogen. This colourless solid is the dioxime derivative of the diketone butane-2,3-dione (also known as diacetyl). DmgH2 is used in the analysis of palladium or nickel. Its coordination complexes are of theoretical interest as models for enzymes and as catalysts. Many related ligands can be prepared from other diketones, e.g. benzil.
cefetamet
Cefetamet is a cephalosporin antibiotic.
cefmenoxime
Cefmenoxime is a third-generation cephalosporin antibiotic.
cyclohexanone oxime
chemical compound
cefozopran
Cefozopran (INN) is a fourth-generation cephalosporin.
norelgestromin
Norelgestromin, or norelgestromine, sold under the brand names Evra and Ortho Evra among others, is a progestin medication which is used as a method of birth control for women. The medication is available in combination with an estrogen and is not available alone. It is used as a patch that is applied to the skin.
(EZ)-Methylethyl ketone oxime
chemical compound
acetoxime
chemical compound
ceftiolene
Ceftiolene (INN) is a third-generation cephalosporin antibiotic.
cefdaloxime
Cefdaloxime (INN) is a third-generation cephalosporin antibiotic.
norgestimate
Norgestimate, sold under the brand name Ortho Tri-Cyclen among others, is a progestin medication which is used in birth control pills for women and in menopausal hormone therapy. The medication is available in combination with an estrogen and is not available alone. It is taken by mouth.
(E)-falintolol
Falintolol is a beta-adrenergic receptor antagonist.
cefmatilen
Cefmatilen (INN, codenamed S-1090) is an orally-active cephalosporin antibiotic. It was developed in Japan and first described in 1992.
technetium (99mTc) exametazime
chemical compound
milbemycin oxime
chemical compound
Alprenoxime
Alprenoxime is a beta blocker. It is a prodrug to alprenolol.
Eplivanserin
Eplivanserin, also known by its former developmental code names SR-46349 and SR-46615 and by its former tentative brand names Ciltyri and Sliwens, is a serotonin 5-HT2A receptor antagonist which was under development by Sanofi Aventis for the treatment of a variety of medical conditions but was never marketed. It is taken orally.